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Radiobiological rationale for stereotactic hypofractionated radiosurgery 
Part II. Normal tissue tolerance — dose constraints
Bogusław Maciejewski1, Sławomir Blamek1, Krzysztof Składowski2, Rafał Suwiński3, Leszek 
Miszczyk1, Krzysztof Ślosarek4, Marcin Miszczyk4
The response of normal tissues/organs to SHRS is more complex than to conventional radiotherapy. Tolerance doses 
TD5/5 and TD50/5, proposed by Rubin and Casarett, cannot be simply used for SHRS. Instead of LQED2, the BED is ad-
vised. The term risk dose (RD) corresponds better than TD to the risk of late morphological and functional disorders 
(OAR). BED doses show a rapid gradient with increasing distance of the OAR from the tumour GTV. Other risk factors 
include the dose-volume relationship, OAR organization (serial or parallel) and the ratio of the FSU to the target 
call. Vasculoendothelial cell damage initiates series of processes resulting in clinical and functional late effect. Using 
available data and studies, RDmin and RDmax for doses are listed as physical and BED doses for various OAR and dose-
-volume constraints. The RD values and constraints are rough estimates, since the available SHRS data are sparse and 
fragmentary, which should be interpreted cautiously and need further clinical validation.
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Radiobiologic mechanisms 
For decades, knowledge about the pathoradiobiology 
and kinetics of normal tissues has been gathered mainly for 
conventional dose fractionation [1–4]. The radiopathology 
underlying late responses to SHRS is much less known [5]. 
Categorization of acute reactions (often transient) develo-
ping in hierarchical and late effects in flexible tissues may 
be misleading, since tissues/organs comprise more than one 
type of cells, each with its own characteristics [1]. Malnutri-
tion and microenvironmental disfunction contribute to the 
death of target cells, and part of them (the residual pool) can 
be recruited to the proliferative pool, inducing “avalanche” 
cell death and functional disorders [1]. 
In SHRS there is a response similar to tumour response, 
except that the 5R’s acute and late effects are also regulated 
by the 3R’s [4–7]. The response to a few large doses compared 
to many conventional 2.0 Gy fractions can be anecdotally com-
pared to a “boxing game”. One challenger is knocked-down in 
the first round by a single strong punch, and another one also 
loses, but by points in the 15th round, receiving many blows 
during each round. The first one will probably recover sooner, 
whereas the second one, who was physically and functionally 
devastated, would need a longer time to recover. This simple 
example reflects Fowler’s statement a lot to a little (volume) is 
better than not too much to a lot. With no doubt, the first part 
is a key principle underlying hypofractionated radiosurgery. 
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The number of serial or parallel functional subunits 
(FSU) with the number of target cells (TC), and volume 
effect significantly influence the incidence and severity of 
late radiation injury induced by conventional fraction doses, 
and the LQED2 formalism has been proven as adequate for 
estimating and comparing equivalent doses [1]. However, 
it unlikely that it would work for SHRS, which uses large 
fractions. An indisputably advantageous characteristic of 
the SHRS is a lot to a little. A large dose is at least intentio-
nally homogeneously distributed within the tumour GTV 
with pronounced and rapid dose reduction within a small 
distance beyond. A theoretical tumour with 3 cm diameter 
(14.1cc — 109.7 cells) and two SHRS regimens of 54 Gy in 
3 fractions (A) and 30 Gy in 3 fractions (B) are used as an 
example (Fig. 1). The dose distributed in surrounding normal 
tissues is transformed into respective BED doses using ?/? 
= 3.0 Gy (Fig. 1.1). This figure illustrates rapid dose reduction 
to 40% of total BED3 at 5 mm and to about 17% at 10 mm 
distance from the GTV margins (Fig. 1.2). As opposed to 
the assumed homogeneous dose distribution within the 
tumour GTV, critical normal tissue/organs receive different, 
small rates of the planned dose. Thus, their response to SHRS 
will depend on the number of the FSUs and its target cells 
involved (volume factor). Other mechanisms (3R’s) which 
also play an important role, depending on the size of single 
or fraction dose, cannot be ignored [6–10].
Response of brain and spinal cord structures and 
other organs 
Sometimes mature neurons are considered as target 
cells, but they are the most radioresistant cells in the CNS, 
and in fact, they are not the primary target, but they do die 
as a result of different indirect pathological processes [1, 4, 7, 
10–12]. Vasculoendothelial cells are the most radiosensitive 
and likely are the primary target for radiation [4, 7, 13]. Its 
deceleration induces a cascade of pathological processes 
which indirectly but irreversibly lead to consequential neural 
damage and functional dysfunction (myelopathy, necrosis). 
Endothelial cell damage, mediated by cytokine TNF-?, indu-
ces a dose-dependent extravasation of serum proteins one 
day after high-dose irradiation, which is a sign of an impaired 
blood-brain barrier [1, 2, 14]. Two to three months later, 
reversible demyelization occurs, which becomes confluent 
in a dose-dependent manner. 
Progressive demyelization, gliosis, and vasogenic oede-
ma lead to further impairment of cellular nutrition [1, 4, 5]. 
Garcia-Barros et al. and Brown et al. reported that these 
pathological processes occur after single doses of 8–10 Gy 
and higher [11, 15]. The severity of vascular damage and 
other consequential effects strongly depend on the dose, 
the irradiated volume of the brain or lengths of the spinal 
cord [1, 4, 13, 16–20]. Some late effects and syndromes can 
be transient like Lhermite’s syndrome [21], which generally 
occurs a few months after spinal cord irradiation as a result 
of transient demyelization. Vascular lesions, oedema, and 
inflammatory effects in the CNS precede any neurological 
changes in astrocytes, microglial, loss of oligodendrocytes 
and subsequently, neurons. Vascular damage also leads 
to post SHRS late damage of the optic nerve [18, 20], and 
indirectly to obliteration of about 88% of the vascular mal-
formation (AUM) nidus [4, 22] after the dose of about 23 Gy 
(BED3 = 199 Gy3).
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Figure 1. Dose gradient in normal tissue surrounding a theoretical tumour irradiated using SHRS with two different regimens (A) and (B) 
(1) — BED3 dose gradient within the distance from GTV margins; 
(2) — rates of BED decrease (from Fig. 1.1) vs distance from the GTV
(1) (2)
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Vascular damage is not only limited to the CNS but also 
occurs in other organs. Capillary endothelial cell damage 
in the lung induces injury of the type II alveolar cells [4, 6, 
18, 23–27], considered by some authors as primary target 
cells [1, 2] in the pulmonary alveolus (FSU). These processes 
are supported by radiation-induced cytokine TGF-? which 
stimulates collagen formation and contributes to both early 
and late pulmonary fibrosis. Damage to the microvascular 
endothelium also induces skin teleangiectases. 
Vascular endothelial cells are also a primary target for 
late heart radiation injury. Their death initiates a sequence 
of lesions in the myocardial vasculature. These effects lead 
then to ischemia and finally to myocardial fibrosis [2, 26]. 
Neither direct damage to myocytes nor coronary arteries 
are the main and primary targets. 
Nephron is a single FSU in the kidney, but major radia-
tion injury occurs at first in the glomerular capillaries and 
precedes tubular depletion, which lead to tubular atrophy 
[18, 29]. Vascular damage also plays an important role in the 
late response of the liver [30, 31] and pancreas, although 
the pathobiology of late radiation effects in these organs 
remains obscure.
In the gastrointentional tract, epithelial mucosal cells 
are recognized as target cells. Rapidly regenerating foci 
in the epithelium appear within 7–14 days, and complete 
epithelial regeneration, for example in the oesophagus, 
can occur 3 months to 2 years after irradiation. Progressive 
vascular damage leading to endarteritis is the critical radia-
tion lesion for late effects [4, 6], and rapid obliteration of 
vessels results in gradual slow fibrosis and narrowing of the 
fine vasculature. The Oesophagus, intestine and bowel are 
tube-like organs and if instead of a part of the oesophageal 
wall, the whole circumference of the tube receives a high 
dose, then vasculoendothelial damage may in the end lead 
to very severe necrosis and fatal perforation.
Although hypoxia is the result of vascular damage after 
SHRS, it may sometimes play a protective role. Depending 
on the intensity of the cell kill, the potential of sublethal 
damage repair can contribute to recovery of some portion 
of injuries until the nutritional and microenvironmental 
condition becomes unfavourable, and then it will induce 
“avalanche” late damage. Repopulation does not play a role 
at all, since treatment is usually very short.
There is still a lack of understanding of the role of the 
immunogenic effects of radiation, especially large doses 
[7]. Cytotoxic T-cells induced by radiation likely influence 
tumour regression, but released cytokines can partly play 
a protective role. Radiation also affects other nonimmune 
cells of microenvironment as lymphocyte extravasation and 
facilitates expansion of myeloid-derived suppressive cells. 
Thus, large dose fractions initiate dichotomous effects of 
immune functions, that means, they could be simultane-
ously both immunostimulatory and immunosuppressive. 
Thus, they may in some way protect late responding normal 
tissues, but in the field of SHRS, available data are vague 
and fragmentary and they mainly come from the bench 
with no clinical validation. SHRS no doubt induces com-
plex mechanisms of normal tissue response to high single 
fractionated doses, but these are rather guessed at than 
quantified and validated. 
Normal tissues/organs dose constraints 
Late radiation effects in normal organs occur as a variety 
of late complications, ranging from those that are confined, 
moderate and tolerable by patients despite the deteriora-
ting quality of life, to the very severe, life threatening and 
even fatal. They manifest usually years after treatment and 
its manifestation is based on probability but not on certainty.
Four to five decades ago, Rubin and Casarett [2, 3] defi-
ned pathomorphological radiation features in normal tissu-
es and they proposed a series of tolerance doses (TD5/5 and 
TD50/5). One can however question the adequacy of these 
terms because “tolerance” refers to patient’s reaction to late 
effects which have already occurred. Thus  “Risk Doses — 
RD5/5 and RD50/5“, seem more appropriate terms because 
they correspond to a 5% or 50% risk of the occurrence of spe-
cific late effects (complications), except for the spinal cord 
with the constraint RD1/5 which should not be surpassed.
The majority of the RD doses and the radiopathobiology 
of normal tissues/organs responses have been established 
empirically due to growing knowledge and experience [4] 
but usually they are rather quasi-quantitavely guessed than 
precisely estimated. Nowadays, these empirical guidelines 
should be interpreted cautiously because they do not fully 
and precisely reflect the underlying complex of pathological 
and functional processes resulting from differences in dose 
distribution. 
SHRS regimens offer two important strengths. The first 
is intentionally homogeneous high dose distribution within 
the tumour GTV (overdosage is accepted) and the second, 
significant dose decrement within a relatively short distance 
(in mm) from the GTV margins (Fig. 1). Therefore, the dose 
which is received in all or in part of a critical normal organ 
and the consequences thereof strongly depend among 
other factors on its relative localization to the tumour mar-
gins. 
There are a few different SHRS regimens most often 
used in practice, generally from 10–30 Gy of single fraction 
to various doses given in 3, 4 or 5 fractions. Using data from 
Park et al. [9] and Siva et al. [26], 0.4 × BED2 and 0.17 × BED2 
for normal lung have been estimated (rates taken from Fig.1) 
for various SHRS regimens (Tab. I). The results show that 
0.17 × BED2 doses (probably except for 60 Gy and 66 Gy 
given in 3 fx) do not theoretically exceed tolerance con-
straints for this organ. No late pulmonary complications 
were noted after delivery of 45 Gy / 3 fx, 50 Gy / 5 fx, 60 Gy 
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/ 5 fx and even after 30 Gy / 1 fx, however 9% of late lung 
complications occurred after 30 Gy / 1 fx, 60 Gy / 4 fx, and 
surprisingly also 5% after 24 Gy / 3 fx. In light of these results, 
Siva and Slotman [26] rightly ask where is the evidence and 
what are we doing with it?
A prospective phase I trial on peripheral stage T1–T2 
NSCLC [24] revealed that 60 Gy / 3 fx (0.17 BED2 = 112 Gy2) 
did not exceed the tolerance constraint, but 66 Gy / 3 fx (0.17 
BED2 = 135 Gy2) did. It is not easy to establish constraint BEDs 
for different SHRS regimens (Tab. I). The suggestion that 
the BED3 of 100 Gy3 (?/? = 3.0 Gy) might be a commonly
accepted RD dose as a tolerance constraint for late respon-
ding normal tissue [8] sounds unreasonabe and raises some 
uncertainties, at least because dose distribution within the 
organ at risk or part of it and the distance to the tumour 
GTV strongly influence differences in the RD constraints.
The Risk Doses (mean and max) presented in Tables 
II and III have mainly been deduced and compiled based 
on many data sets published in the literature, more or less 
detailed and often fragmentary. Morphological and clinical 
features of late effects are rather concise and sometimes 
uncertain regarding the volume of the organ involved (e.g. 
the inner or outer part of the kidney), and it distance to the 
tumour GTV. Therefore, the RD doses shown in Table II and III 
should be cautiously interpreted as approximate guidelines 
rather than obligatory. 
SHRS has been primarily used for CNS tumours and later 
extended also to extracranial tumours. This explains why 
more detailed data are in Table II than in Table III. Retro-
spective CFRT and prospective SHRS data allow comparison 
of the risk of brain necrosis (RBN) depending on the BED 
values estimated for these two types of radiotherapy. Figure 
2 shows that the increasing risk of the RBN correlates with 
lower SHRS — BEDs than with CFRT-BEDs. Flickinger et al. [6, 
22] published interesting and unique data regarding the risk
of late injury in various regions of the brain after irradiation 
with a single dose of 12 Gy (BED2 = 84 Gy2), which depended
on localization of the arteriovenous malformation (AVM) in 
the brain with the volume of the AVM (Fig. 3). Historical data 
by Van Dyk et al. [27] show that RD of about 8 Gy (BED2 = 40 
Gy2) correlates with a 5% risk of late pneumonitis, but it also 
depends on the irradiated volume (Fig. 4). These examples 
warn against acceptance the BED3 of 100 Gy3 as the uni-
versal cut-off risk dose, because for some organs the BED 
constraint should not be higher than 40–60 Gy. The kidney 
constraint dose reported by Timmerman et al. [10] depends 
on the involved volume of the kidney. If the renal cortex is 
involved, the critical volume of 200 cc should not receive a 
single dose higher than 8.4 Gy (BED2 = 45 Gy2), whereas in 
the case of the renal hilum, the dose constraint for 2/3 of the 
kidney can receive a single dose of 10.4 Gy (BED2 = 64 Gy2). 
Nevertheless, both constraints are far below the BED = 100 
Gy, proposed by Yang et al. [8] as “safe” for normal tissues. 
Despite various pathoradiobiological mechanisms, the 
low constraint dose for kidney (as for some other organs as 
Table I. Biologically effective doses (BED2.0) estimated for a hypothetical 
normal organ (?/? = 2.0 Gy) with distance coefficients to the tumour GTV 
(taken from Fig. 2) for SHRS regimes from Park et al. [9] 
SHRS
regimens
(tumour)
Normal lung (?/? = 2.0 Gy)
0.4 × BED2*
(5 mm distance)
0.17 BED2*
(10 mm distance)
24 Gy / 3 fx 48 Gy2 20 Gy2
25 Gy / 1 fx 135 Gy2 57 Gy2
30 Gy / 1 fx 192 Gy2 82 Gy2
45 Gy / 3 fx 153 Gy2 65 Gy2
48 Gy / 4 fx 134 Gy2 57 Gy2
50 Gy / 5 fx 172 Gy2 51 Gy2
60 Gy / 3 fx 264 Gy2 112 Gy2
60 Gy / 4 fx 204 Gy2 87 Gy2
60 Gy / 5 fx 168 Gy2 71 Gy2
66 Gy / 3 fx 317 Gy2 135 Gy2
*BED2 was calculated for lung in the respective distance from the tumour GTV
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Figure 2. Comparison of radiation brain necrosis related to the BED doses of SHRS (w) with that of CFRT (r) (based on data [4] and [11])
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Table II. Physical and BED
 dose constraints for SHRS to CN
S (estim
ated and com
piled based on data sets of [1, 4–6, 10, 12–22]
O
rgan/tissue
SIN
G
LE D
O
SE
Fractionated dose
Volum
e (D
ose)
constraints
Late effects
Physical (Gy)
BED
 (Gy?/? )
Physical (Gy)
BED
 (Gy?/? )
m
ean
m
ax
m
ean
m
ax
m
ean
m
ax
m
ean
m
ax
BRA
IN
STEM
 (?/? = 2 Gy) 
10
13
60
98
18/3 fx
26/5 fx
– –
24/3 fx 
30/5 fx
72 
94
– –
120 
120
< 1.0 cc
< 10. cc
cranial
neuropathy
SPIN
A
L CO
RD
 (?/? = 3 Gy)
10
13
60
98
18/3 fx
24/5 fx
– –
21/3 fx 
25/5 fx
54 
56
– –
70 
67
V
10  < 0.35 cc, V
14 < 0.03 cc
V
18 < 0.25 cc
m
yelitis
CAU
D
A EQ
U
IN
A
 (?/? = 3 Gy)
14
16
79
102
22/3 fx 
30/5 fx
– –
24/3 fx
34/5 fx
76 
90
– –
88 
106
V
14  < 5cc, V
16 < 0.03cc
< 5 cc
neuritis
O
PTIC TRACT (?/? = 2 Gy)
and CH
IA
SM
8
10
40
60
15/3 fx
20/5 fx
– –
19.5/3 fx
25/5 fx
53 
60
– –
83 
88
< 0.2 cc
< 0.2 cc
RIO
N
 —
 radiation 
induced neuropathy 
(cataract, retinitis, 
im
paired vision)
IN
TRACRA
N
IA
L N
ERVES
nerve II
nerve V, VII, VIII  (?/? = 3 Gy)
nerve III, IV, VI
8 
12 
15
10 
15 
18
40 
60 
90
60 
90 
126
not reported
not reported
not reported
– –  
–
not reported
not reported
not reported
neuropathy
BRA
IN
 A
RTERIO
VEN
O
U
S 
M
A
LFO
RM
ATIO
N
(AVM
) (?/? = 2Gy)
12
not 
reported
84
not 
reported
not reported
–
TD
5/5
frontal lobe: V < 35 cc
tem
poral lobe: V < 15 cc
cerebella: V < 13 cc
m
edulla: V < 5 cc
neurologic
perm
anent
injury
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Table III. Physical and BED
 dose constraints for SHRS to CN
S to selected norm
al organs [estim
ated and com
piled based on data sets [1, 3, 5, 6, 10, 18, 23–31] 
O
rgan/tissue
SIN
G
LE D
O
SE
Fractionated dose
Volum
e (D
ose)
constraints
Late effects
Physical (Gy)
BED
 (Gy?/? )
Physical (Gy)
BED
 (Gy?/? )
m
ean
m
ax
m
ean
m
ax
m
ean
m
ax
m
ean
m
ax
LU
N
G
 (?/? = 2 Gy) 
7.4
8.8
35
48
11.4 / 3 fx
13.5 / 5 fx
– –
15 / 3 fx 
18 / 5 fx
3332
– –
53 
50
< 4 cc critical 1000 cc
< 4 cc
pneum
onitis
G3 < 2%
: 
50 Gy / 10 fx
             48 Gy / 4 fx
             26 Gy / 1 fx
TRACH
EA IPSILATERA
L 
BRO
N
CH
U
S (?/? = 3 Gy)
8.8
20
35
150
15 / 3 fx
18 / 5 fx
– –
30 / 3 fx 
38 / 5 fx
4040
– –
130 
134
< 4 cc
< 3 cc
stenosis, fistula
H
EA
RT (?/? = 3.7 Gy)
16
22
85
153
24 / 3 fx
32 / 5 fx
– –
30 / 3 fx 
38 / 5 fx
7487
– –
111 
116
< 15cc, V
16 < 15 cc
< 15 cc
pericarditis
LIVER (?/? = 2.5 Gy)
9
12
41
70
17/3 fx
21/5 fx 
– –
not reported 
not reported
5656
– –
– –
< 700 cc
G3 < 2%
 —
 60 Gy / 3fx
G3 = 0%
 —
 14–25 Gy / 1 fx
                 30 Gy / 3 fx
                 50 Gy / 5 fx
G3 < 2%
: V
30 ? 60%
RILD
 —
 radiation 
induced liver disease 
KID
N
EY (?/? = 3 Gy)
8.4
10.6
4460
67 
90
14.4/3 fx
17.5/5 fx
– –
18.6/3fx 
23/5fx
4948
– –
76 
76
< 200cc; V
10  —
 35%
 vol.
V
16  < 15 cc
chronic nephropathy
hypertension
PA
N
CREA
S (?/? = 2 Gy)
not reported
12
not reported
84
21/3 fx
25/5 fx
– –
not reported 
not reported
9588
– –
– –
BED
 < 100 Gy
2.0
standard: chem
oradiation
gastro duodenal 
late injury
PRO
STATE (?/? = 2 Gy)
low
 and interm
ediate risk
not reported
–
not reported 
–
not reported 
–
30/5 fx – 40/5 fx
not reported
–
120–200
GI < 3; < 2%
GU < 3; < 1%
late bladder/rectal effect
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well) reflects not only a low ?/? value but also depends on 
the FSU organization. The kidney is an excellent example of 
the importance of the organ’s cellular organization. A kidney 
contains more or less about 1011 target clonogenic tabular 
cells organized as 104 cells in each of 107 nephrons (FSUs). 
From the radiobiological point of view, most of them will re-
cover after a dose reducing survival to 10–4 (37% of nephrons 
will survive). However, if renal target cells were organized 
in a different way, namely 107 target cells in 104 nephrons, 
then 37% of nephrons would survive after reduction of 
cell survival to no more than 10–7, which would result in an 
increase of constraint RD by 75% (7/4). This example shows 
how important collection of detailed and validated data on 
dose/fractionation is, distributed to all or a defined part of 
a normal organ, on dose gradients distributed within them 
and on specific, not general, clinical and functional late 
injures, including the time of its occurrence.
In the present review, data have been selected and 
interpreted as precisely as possible. However, we have 
not been able to clarify some uncertainties and “blank 
points”. Therefore, in conclusion, it is advised to consider 
cautiously presented and compiled dose constraints (RD) 
for various normal organs, with some measure of criticism 
because many of them are not definitive, obligatory and 
are as yet unvalidated, but they are rather approximated 
guidelines. 
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